Literature DB >> 18285589

Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma.

Muluken Melese1, Wondu Alemayehu, Takele Lakew, Elizabeth Yi, Jenafir House, Jaya D Chidambaram, Zhaoxia Zhou, Vicky Cevallos, Kathryn Ray, Kevin Cyrus Hong, Travis C Porco, Isabella Phan, Ali Zaidi, Bruce D Gaynor, John P Whitcher, Thomas M Lietman.   

Abstract

CONTEXT: Treatment recommendations assume that repeated mass antibiotic distributions can control, but not eradicate or even locally eliminate, the ocular strains of chlamydia that cause trachoma. Elimination may be an important end point because of concern that infection will return to communities that have lost immunity to chlamydia after antibiotics are discontinued.
OBJECTIVE: To determine whether biannual treatment can eliminate ocular chlamydial infection from preschool children and to compare results with the World Health Organization-recommended annual treatment. DESIGN, SETTING, AND PARTICIPANTS: A cluster-randomized clinical trial of biannual vs annual mass azithromycin administrations to all residents of 16 rural villages in the Gurage Zone, Ethiopia, from March 2003 to April 2005.
INTERVENTIONS: At scheduled treatments, all individuals aged 1 year or older were offered a single dose of oral azithromycin either annually or biannually. MAIN OUTCOME MEASURE: Village prevalence of ocular chlamydial infection and presence of elimination at 24 months in preschool children determined by polymerase chain reaction, correcting for baseline prevalence. Antibiotic treatments were performed after sample collections.
RESULTS: Overall, 14,897 of 16,403 eligible individuals (90.8%) received their scheduled treatment. In the villages in which residents were treated annually, the prevalence of infection in preschool children was reduced from a mean of 42.6% (range, 14.7%-56.4%) to 6.8% (range, 0.0%-22.0%) at 24 months. In the villages in which residents were treated biannually, infection was reduced from 31.6% pretreatment (range, 6.1%-48.6%) to 0.9% (range, 0.0%-4.8%) at 24 months. Biannual treatment was associated with a lower prevalence at 24 months (P = .03, adjusting for baseline prevalence). At 24 months, no infection could be identified in 6 of 8 of those treated biannually and in 1 of 8 of those treated annually (P = .049, adjusting for baseline prevalence).
CONCLUSION: Local elimination of ocular chlamydial infection appears feasible even in the most severely affected areas, although it may require biannual mass antibiotic distributions at a high coverage level. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00221364.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285589     DOI: 10.1001/jama.299.7.778

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  40 in total

1.  Annual Versus Biannual Mass Azithromycin Distribution and Malaria Parasitemia During the Peak Transmission Season Among Children in Niger.

Authors:  Catherine E Oldenburg; Abdou Amza; Boubacar Kadri; Beido Nassirou; Sun Y Cotter; Nicole E Stoller; Sheila K West; Robin L Bailey; Travis C Porco; Jeremy D Keenan; Thomas M Lietman; Bruce D Gaynor
Journal:  Pediatr Infect Dis J       Date:  2018-06       Impact factor: 2.129

2.  Association of conjunctival bacterial infection and female sex in cicatricial trachoma.

Authors:  Vicky Cevallos; John P Whitcher; Muluken Melese; Wondu Alemayehu; Elizabeth Yi; Jaya D Chidambaram; Scott Lee; Harsha Reddy; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-07       Impact factor: 4.799

3.  Slow resolution of clinically active trachoma following successful mass antibiotic treatments.

Authors:  Jeremy D Keenan; Takele Lakew; Wondu Alemayehu; Muluken Melese; Jenafir I House; Nisha R Acharya; Travis C Porco; Bruce D Gaynor; Thomas M Lietman
Journal:  Arch Ophthalmol       Date:  2011-04

4.  Association of Chlamydia trachomatis ompA genovar with trachoma phenotypes.

Authors:  Stephanie A Chin; Wondu Alemayehu; Muluken Melese; Takele Lakew; Vicky Cevallos; Thomas M Lietman; Jeremy D Keenan
Journal:  Eye (Lond)       Date:  2018-03-05       Impact factor: 3.775

5.  Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma.

Authors:  Jeremy D Keenan; Takele Lakew; Wondu Alemayehu; Muluken Melese; Travis C Porco; Elizabeth Yi; Jenafir I House; Zhaoxia Zhou; Kathryn J Ray; Nisha R Acharya; John P Whitcher; Bruce D Gaynor; Thomas M Lietman
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

6.  The epidemiological dynamics of infectious trachoma may facilitate elimination.

Authors:  Thomas M Lietman; Teshome Gebre; Berhan Ayele; Kathryn J Ray; M Cyrus Maher; Craig W See; Paul M Emerson; Travis C Porco
Journal:  Epidemics       Date:  2011-04-06       Impact factor: 4.396

7.  Sanitation and health.

Authors:  Duncan Mara; Jon Lane; Beth Scott; David Trouba
Journal:  PLoS Med       Date:  2010-11-16       Impact factor: 11.069

Review 8.  Strategies to control trachoma.

Authors:  Anu A Mathew; Angus Turner; Hugh R Taylor
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

9.  Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution.

Authors:  Takele Lakew; Wondu Alemayehu; Muluken Melese; Elizabeth Yi; Jenafir I House; Kevin C Hong; Zhaoxia Zhou; Kathryn J Ray; Travis C Porco; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25

10.  When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries.

Authors:  Kathryn J Ray; Thomas M Lietman; Travis C Porco; Jeremy D Keenan; Robin L Bailey; Anthony W Solomon; Matthew J Burton; Emma Harding-Esch; Martin J Holland; David Mabey
Journal:  PLoS Negl Trop Dis       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.